biomarkers

In 2024, we saw the expanded use of synthetic data and natural language processing transform drug discovery and development. In a batch of predictions published in December of 2023, one expert predicted that synthetic data was set to “take off” in drug research. In 2025, the pendulum could begin swinging back the other way, according…

The digital pathology firm PathAI has released PathExplore Fibrosis, an AI-based tool that analyzes fibrosis and collagen structures from H&E-stained whole-slide tissue images. The software quantifies fibrotic areas and collagen fibers from standard pathology slides, replacing specialized staining techniques and microscopy equipment. The tool processes large datasets of tissue images, designed to work with existing…

A new study, published in the Journal of Clinical Investigation, suggests that identifying distinct immune “signatures” in patients may help oncologists predict and prevent adverse events associated with immunotherapy. This observational study, reportedly the largest of its kind, prospectively enrolled 111 patients with solid tumors receiving immune checkpoint inhibitor (ICI) therapy at Johns Hopkins. Researchers…

Imagine sifting through medical and genetic histories to understand why some patients respond to treatments while others don’t. This is the reality for companies like Merck & Co. A recent pact with Culmination Bio is giving Merck access to more than 40 years of data, including millions of biospecimens to fuel this aim. “We want…

Endometriosis, a condition where endometrial tissue grows outside the uterus, has a strong genetic underpinning. A new study published in the Journal of Molecular Diagnostics sheds light on this connection. Researchers from a team including Genzeva, LumaGene, RYLTI Biopharma, Brigham & Women’s Hospital of Harvard University and QIAGEN Digital Insights used a unique approach in…

Alzheimer’s disease research appears to be hitting its stride, thanks to recent therapeutic advances in drug development and the emergence of biomarkers to detect the condition. “All the pieces of the puzzle of precision medicine, which is already quite common in oncology, are now in place,” said Hartmuth Kolb, vice president, neuroscience biomarkers and R&D…

The journey to developing a successful drug, theoretically, may appear linear: you discover the right drug, find the suitable patient and administer it at the right time. The reality, however, often deviates from this straightforward path. Aligning these three variables remains notoriously difficult, often leading to elongated timelines strewn with failures, sometimes extending over a…

The Estée Lauder family has donated $200 million to the Alzheimer’s Drug Discovery Foundation (ADDF), a nonprofit they founded in 1998 to support Alzheimer’s research. The gift is the largest ADDF has received. “We’ve deployed about $270 million so far for about 700 programs in 19 countries of drug discovery and development over the past…

The accepted definition of a biomarker is a “defined characteristic that is measured as an indicator of normal biological processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions.” This definition was derived from a 2016 partnership between the U.S. FDA and the National Institutes of Health (NIH). Biomarkers are not diagnostic…

What do cupcakes have to do with oncology, and more specifically, predictive diagnostics? Before I explain, I’ll provide some context. I recently came across an image that illustrated the difference between how Doppler radar detects conditions for a Tornado Watch versus a Tornado Warning using cupcakes.1 One side of the graphic shows each of the…